Genmab has been under the spotlight with its stock performance receiving mixed reactions from analysts. Various adjustments to price targets have been made including JPMorgan and Leerink Partners raising their respective targets. Observations citing Genmab as a profitable growth stock have been echoed, alongside reports of their continued share buy-back program. Significant antitumor data from the oncology portfolio have been credited with driving growth. Positive trial results and share moves have been noted, while the stock has equally experienced downgrades as seen by Bernstein. Legal challenges have also been a part of the journey, exemplified by a lawsuit from AbbVie. Still, despite certain setbacks and fluctuations, many maintain a positive outlook on the stock due to financial robustness and strategic positioning. Approval of Genmab treatments in Japan and dismissal of the AbbVie lawsuit have been among recent developments. The ongoing share buy-back scheme and Q1 2025 results that outperformed expectations affirm the company's confidence.
Genmab Stocks News Analytics from Tue, 20 Aug 2024 07:00:00 GMT to Fri, 06 Jun 2025 17:15:36 GMT -
Rating 4
- Innovation 1
- Information 6
- Rumor -5
